WO2002057453A3 - Polypetides and nucleic acids encoding same - Google Patents

Polypetides and nucleic acids encoding same Download PDF

Info

Publication number
WO2002057453A3
WO2002057453A3 PCT/US2001/050331 US0150331W WO02057453A3 WO 2002057453 A3 WO2002057453 A3 WO 2002057453A3 US 0150331 W US0150331 W US 0150331W WO 02057453 A3 WO02057453 A3 WO 02057453A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypetides
acids encoding
encoding same
disclosed
Prior art date
Application number
PCT/US2001/050331
Other languages
French (fr)
Other versions
WO2002057453A2 (en
Inventor
Esha A Gangolli
Meera Patturajan
Corine A M Vernet
Uriel M Malyankar
Ramesh Kekuda
David J Stone
David Anderson
Richard A Shimkets
Catherine E Burgess
Bryan D Zerhusen
Xiaohong Liu
Kimberly A Spytek
Stacie J Casman
Ferenc L Boldog
Glennda Smithson
Li Li
Weizhen Ji
Original Assignee
Curagen Corp
Esha A Gangolli
Meera Patturajan
Corine A M Vernet
Uriel M Malyankar
Ramesh Kekuda
David J Stone
David Anderson
Richard A Shimkets
Catherine E Burgess
Bryan D Zerhusen
Xiaohong Liu
Kimberly A Spytek
Stacie J Casman
Ferenc L Boldog
Glennda Smithson
Li Li
Weizhen Ji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Esha A Gangolli, Meera Patturajan, Corine A M Vernet, Uriel M Malyankar, Ramesh Kekuda, David J Stone, David Anderson, Richard A Shimkets, Catherine E Burgess, Bryan D Zerhusen, Xiaohong Liu, Kimberly A Spytek, Stacie J Casman, Ferenc L Boldog, Glennda Smithson, Li Li, Weizhen Ji filed Critical Curagen Corp
Priority to JP2002558505A priority Critical patent/JP2005508601A/en
Priority to EP01993342A priority patent/EP1352065A2/en
Priority to CA002433313A priority patent/CA2433313A1/en
Publication of WO2002057453A2 publication Critical patent/WO2002057453A2/en
Publication of WO2002057453A3 publication Critical patent/WO2002057453A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2001/050331 2000-12-19 2001-12-19 Polypetides and nucleic acids encoding same WO2002057453A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002558505A JP2005508601A (en) 2000-12-19 2001-12-19 Polypeptide and nucleic acid encoding it
EP01993342A EP1352065A2 (en) 2000-12-19 2001-12-19 Polypetides and nucleic acids encoding same
CA002433313A CA2433313A1 (en) 2000-12-19 2001-12-19 Polypetides and nucleic acids encoding same

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US26570400P 2000-12-19 2000-12-19
US60/256,704 2000-12-19
US25731400P 2000-12-20 2000-12-20
US60/257,314 2000-12-20
US28815301P 2001-05-02 2001-05-02
US60/288,153 2001-05-02
US29407501P 2001-05-29 2001-05-29
US60/294,075 2001-05-29
US30750601P 2001-07-24 2001-07-24
US60/307,506 2001-07-24
US31159001P 2001-08-10 2001-08-10
US31161301P 2001-08-10 2001-08-10
US60/311,613 2001-08-10
US60/311,590 2001-08-10
US31561701P 2001-08-29 2001-08-29
US60/315,617 2001-08-29
US32235801P 2001-09-14 2001-09-14
US60/322,358 2001-09-14

Publications (2)

Publication Number Publication Date
WO2002057453A2 WO2002057453A2 (en) 2002-07-25
WO2002057453A3 true WO2002057453A3 (en) 2003-08-14

Family

ID=27578753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050331 WO2002057453A2 (en) 2000-12-19 2001-12-19 Polypetides and nucleic acids encoding same

Country Status (3)

Country Link
JP (1) JP2005508601A (en)
CA (1) CA2433313A1 (en)
WO (1) WO2002057453A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1234031T (en) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, a novel immunoregulatory molecule
US7122345B2 (en) 2001-01-09 2006-10-17 Curagen Corporation Nucleic acid encoding a NOVX13 polypeptide
WO2003038094A1 (en) * 2001-10-30 2003-05-08 Bayer Healthcare Ag Regulation of human glucose transporter
WO2003054190A1 (en) * 2001-12-21 2003-07-03 Takeda Chemical Industries, Ltd. Novel proteins and dnas thereof
WO2004106935A2 (en) * 2003-05-27 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2005079840A2 (en) * 2004-02-20 2005-09-01 Develogen Aktiengesellschaft Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
MX2007004176A (en) 2004-10-06 2007-06-15 Mayo Foundation B7-h1 and methods of diagnosis, prognosis, and treatment of cancer.
WO2006055704A2 (en) * 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
JPWO2006062135A1 (en) * 2004-12-07 2008-06-12 独立行政法人理化学研究所 Diagnostic agents for mental disorders
EP2356251A1 (en) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
WO2001072961A2 (en) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Novel compounds
WO2002046409A2 (en) * 2000-12-06 2002-06-13 Curagen Corporation Proteins and nucleic acids encoding same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
WO2001072961A2 (en) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Novel compounds
WO2002046409A2 (en) * 2000-12-06 2002-06-13 Curagen Corporation Proteins and nucleic acids encoding same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 1 October 2000 (2000-10-01), XP002223479, retrieved from EMBL Database accession no. Q9NQ36 *
GRIMMOND SEAN ET AL: "Cloning, mapping, and expression analysis of a gene encoding a novel mammalian EGF-related protein (SCUBE1).", GENOMICS, vol. 70, no. 1, 15 November 2000 (2000-11-15), pages 74 - 81, XP002223477, ISSN: 0888-7543 *
GRIMMOND SEAN ET AL: "Expression of a novel mammalian epidermal growth factor-related gene during mouse neural development.", MECHANISMS OF DEVELOPMENT, vol. 102, no. 1-2, April 2001 (2001-04-01), pages 209 - 211, XP002223478, ISSN: 0925-4773 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators

Also Published As

Publication number Publication date
JP2005508601A (en) 2005-04-07
CA2433313A1 (en) 2002-07-25
WO2002057453A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
WO2002014368A8 (en) Proteins and nucleic acids encoding the same
WO2002006339A3 (en) Proteins and nucleic acids encoding same
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2001081578A3 (en) Novel proteins and nucleic acids encoding same
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002016599A3 (en) Proteins and nucleic acids encoding same
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2002055702A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2001066747A3 (en) Proteins named fctrx and nucleic acids encoding same
WO2002066643A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2433313

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002558505

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001993342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002245183

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001993342

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001993342

Country of ref document: EP